Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More
Xconomy
AUGUST 19, 2016
This time for me, it’s volleyball. And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. —The FDA last summer approved two new cholesterol fighting drugs known as PCSK9 inhibitors, but so far the market has rejected them, resulting in paltry sales.
Let's personalize your content